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Background: Recent epidemiological studies demonstrate that both active and involuntary exposure to tobacco
smoke increase the risk of breast cancer. Little is known, however, about the molecular mechanisms by which
continuous, long term exposure to tobacco smoke contributes to breast carcinogenesis because most previous
studies have focused on short term treatment models. In this work we have set out to investigate the progressive
transforming effects of tobacco smoke on non-tumorigenic mammary epithelial cells and breast cancer cells using
in vitro and in vivo models of chronic cigarette smoke exposure.
Results: We show that both non-tumorigenic (MCF 10A, MCF-12A) and tumorigenic (MCF7) breast epithelial cells
exposed to cigarette smoke acquire mesenchymal properties such as fibroblastoid morphology, increased
anchorage-independent growth, and increased motility and invasiveness. Moreover, transplantation experiments in
mice demonstrate that treatment with cigarette smoke extract renders MCF 10A cells more capable to survive and
colonize the mammary ducts and MCF7 cells more prone to metastasize from a subcutaneous injection site,
independent of cigarette smoke effects on the host and stromal environment. The extent of transformation and the
resulting phenotype thus appear to be associated with the differentiation state of the cells at the time of exposure.
Analysis by flow cytometry showed that treatment with CSE leads to the emergence of a CD44hi/CD24low
population in MCF 10A cells and of CD44+ and CD49f + MCF7 cells, indicating that cigarette smoke causes the
emergence of cell populations bearing markers of self-renewing stem-like cells. The phenotypical alterations
induced by cigarette smoke are accompanied by numerous changes in gene expression that are associated with
epithelial to mesenchymal transition and tumorigenesis.
Conclusions: Our results indicate that exposure to cigarette smoke leads to a more aggressive and transformed
phenotype in human mammary epithelial cells and that the differentiation state of the cell at the time of exposure
may be an important determinant in the phenotype of the final transformed state.
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Multiple epidemiological studies have established the
association between active and involuntary exposure to
tobacco smoke and increased risk of breast cancer. The
link, which has been a controversial topic for many
years, was initially demonstrated in younger, primarily
premenopausal women [1,2], and subsequently in post-
menopausal women [2-4]. The epidemiological evidence
is backed up by several studies showing that tobacco
carcinogens are present and active in the breast tissue of
smokers [1,5-7]. Except for the documented formation
of mutagenic DNA adducts [6,8], it is unclear how these
compounds affect cell behavior in the breast contribut-
ing to cancer development, progression, and metastasis.
Emerging evidence suggests that cigarette smoke con-
densate (CSC), or aqueous cigarette smoke extract
(CSE) can induce changes in morphology and gene ex-
pression indicative of epithelial to mesenchymal transi-
tion (EMT) in immortalized human bronchial epithelial
cells [9] and in lung carcinoma cells [9,10]. This implies
the acquisition of mesenchymal properties, including
traits that are associated with malignancy such as in-
creased motility and invasiveness [11]. Although these
studies provide some mechanistic data on tobacco
smoke tumorigenesis in lung, data for breast cancer are
limited. In this work we have set out to investigate the
progressive transforming effects of tobacco smoke on
non-tumorigenic mammary epithelial cells and breast
cancer cells using in vitro and in vivo models. Our
results indicate that exposure to cigarette smoke leads
to a more aggressive and transformed phenotype in hu-
man mammary epithelial cells, and that the differenti-
ation state of the cell at the time of exposure may be an
important determinant in the phenotype of the final
transformed state.
Results
Cigarette smoke induces anchorage-independent cell
growth, migration, invasion and morphological changes
in mammary epithelial cells and breast cancer cells
It has been shown that the risk of developing cancer in-
creases with the number of years a person has smoked
or been exposed to second hand smoke [12,13]. For this
reason we developed a model to study the progressive,
chronic effects of cigarette smoke exposure. Cells were
continuously cultured for 72 weeks with an aqueous
cigarette smoke extract (CSE) from main stream smoke
prepared in our laboratory (0.25%, 0.5% or 1% CSE) or for
approximately 40 weeks with cigarette smoke condensate
(CSC) a commercial product based on condensate from
second-hand-like smoke (10 μg/ml or 25 μg/ml CSC). A
concentration of 0.5% CSE, or 25 μg/ml CSC in the media
corresponds to approximately 0.001 cigarettes/ml, which
is an amount comparable to, or lower than those used inother studies [9,10,14-16]. The corresponding amount of
nicotine in the media (1.3±0.1 μg/ml) approximates the
upper limit of the concentrations of cotinine found in the
plasma or breast milk of smokers, which has been
reported as high as 300–800 ng/ml and 200–500 ng/ml,
respectively [17]. Non-tumorigenic MCF 10A cells cul-
tured with either CSE or CSC were transferred to soft agar
to assess anchorage-independent growth after 15, 21, 27
and 39 or 37 weeks of treatment. Both CSE and CSC
caused a significant increase in colony formation in soft
agar (up to 42 fold; Figure 1A) which is a feature typical of
cancer cells. Linear regression analysis indicated that the
effect was both dose and time dependent as the number
of colonies increased in parallel with the duration of treat-
ment (r2>0.9; P<0.05 by F-test), and the concentration of
CSE or CSC (P<0.01 by F-test). The vehicle control for
CSC, which contains DMSO, led to the development of
slightly more colonies than the saline control for CSE.
Treatment with CSE also increased the migratory ability
in MCF10As. After treatment with 0.5% or 1% CSE for 37
weeks MCF 10A cells showed a 3.1 and 3.6 fold increase
in migration, respectively (Figure 1B). The experiment
was replicated after 72 weeks of treatment with similar re-
sults, suggesting that the initial increase in motility is
maintained during prolonged exposure to CSE (Figure 1B).
To test whether colony formation and migration were
unique to MCF10As or would also occur in other breast
cell lines we treated non-tumorigenic, MCF-12A cells with
CSC and the breast cancer cell line MCF7 with CSE. For
MCF12A, we observed a 4 to 5-fold increase in colony
formation after 18 weeks of treatment (Figure 1C, P<0.01
by Student’s t-test) and a significant increase in migration
when exposed to CSC for 18 weeks (Figure 1D). MCF7
cells are capable of forming colonies without CSE treat-
ment; however, a significant increase in colony formation
was observed after only nine weeks of treatment with
0.5% CSE (Figure 1E). Moreover MCF7 cells, which are
more motile then MCF 10A and -12A, and have the ability
to migrate through matrigel coated filters, showed a
marked increase of their invasive capability when ex-
posed to 0.25% or 0.5% CSE for 9 weeks (Figure 1F). All
cell lines tested altered their morphology when exposed
to CSE or CSC. Untreated MCF 10A and MCF-12A cells
normally display a typical cobblestone epithelial morph-
ology in culture. Treatment with CSE or CSC caused
them to adopt a more spindle shape and fibroblast-like
morphology (shown clearly in the inserts, upper and
middle panels, Figure 2), which is consistent with the
increased motility that we observed in the migration as-
says shown in Figure 1. Similarly, MCF7 cells also be-
came more elongated and spindle-shaped after exposure
to cigarette smoke (Figure 2, bottom panel). The ob-
served changes in morphology and motility are consist-
ent with phenotypical changes associated with EMT,
Figure 1 Cigarette smoke induces anchorage-independent cell growth, migration, and invasion in mammary epithelial cell lines. (A)
Treatment of MCF10A cells with CSE or CSC leads to soft agar colony formation that increases, as compared to mock, with increased weeks of
exposure. (B) Treatment of MCF10A cells with CSE for 37 and 72 weeks leads to increased migration through uncoated transwell inserts as
compared to mock treated cells. (E) Treatment of MCF 7 cells with CSE for 9 weeks leads to soft agar colony formation as compared to mock.
(F) Treatment of MCF 7 cells with CSE for 9 weeks leads to increased invasion through matrigel-coated transwell inserts as compared to mock.
(C) Treatment of MCF12A cells with CSC for 18 weeks leads to increased colony formation as compared to mock. (D) Treatment of MCF12 A cells
with CSC leads to increased migration through uncoated transwell inserts as compared to DMSO control The increase in MCF-12A migration
(right) was not quantified numerically because the cells became partially confluent after migration and could not be accurately counted. The dark
patches are cells stained with crystal violet that have migrated though the filter pores (light grey dots); the size bar represents 100 μm. Data in
bar graphs are mean ± standard deviation of 3–5 replicates; *P<0.05, **P<0.01, ***P<0.001 by Student’s t-test.
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may cause breast epithelial cells to acquire mesenchy-
mal properties, which would render them more motile
[11]. For cells that are already tumorigenic, such as
MCF7, our observations suggest that the phenotype has
become more invasive. Similar results were observed
using either CSE or CSC, indicating that both main-
stream smoke and second hand cigarette smoke contain
compounds that can significantly alter the phenotype of
these diverse cell lines.CSE confers the ability to colonize mammary ducts and
metastasize to mammary epithelial cells and breast
cancer cells, respectively
MCF 10A cells are not able to form tumors in immuno-
deficient mice, and are thus neither malignant nor
tumorigenic. Based on our in vitro results, we hypothe-
sized that treatment with CSE might drive these cells to
become more invasive or pre-malignant. To investigate
this scenario, we used an intraductal transplantation
model originally developed to study ductal carcinoma in
Figure 2 Cigarette smoke induces morphological alterations in mammary epithelial cell lines. Photomicrographs showing morphological
alterations of MCF 10A cells exposed to CSE for 44 weeks, MCF-12A cells exposed to CSC for 21 weeks, and MCF7 cells exposed to CSE for 4
weeks. Inserts highlight the spindle shape of cells treated with CSE or CSC. The size bar represents 50 μm.
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the nipple, into the primary mammary duct, which allows
in situ analysis of intraductal growth and/or invasion
through the basement membrane into the stroma [18].
MCF 10A cells treated with 0.5% CSE for 46 weeks or
mock treated were injected into the primary inguinal
mammary ducts of 8-week-old female immunodeficient
mice (NSG). The mammary fat pads were harvested
after three months and labeled with an antibody for
human cytokeratin-18 to identify the injected human
cells. Untreated MCF 10A cells did not appear to
colonize or grow in the ducts; however, colonies of CSE-
treated MCF 10A cells were found within the ducts up
to 3 months post-injection (Figure 3A). We then investi-
gated if CSE could further increase the invasiveness of
MCF7 breast cancer cells. Because these cells are
tumorigenic, and grow much faster than MCF 10A, we
harvested the mammary glands seven days after intra-
ductal injection. At that time, untreated MCF7 cells had
formed several intraductal masses that appeared to
remain within the confines of the ducts. In contrast,
MCF7 cells treated with CSE for 21 weeks had invaded
through the duct and had formed colonies in the stroma
(Figure 3B). Since treatment with CSE had clearly in-
creased the invasiveness of MCF7 cells, we investigated
if tumorigenesis and metastasis of MCF7 cells were alsoaffected using a subcutaneous xenograft model. Trans-
planted MCF7 cells treated with 0.5% CSE for 18 weeks
resulted in smaller tumors than mock-treated cells
(Figure 3C); however, these smaller tumors were associ-
ated with metastases in the lungs of all animals and iso-
lated` cells were found in the liver of at least one animal
(Figure 3D). The three mice shown are representative,
and two additional mice injected with CSE treated cells
were analyzed by gross pathology for a total of 5. In
contrast, we did not observe metastases from untreated
MCF7 cells, suggesting that cigarette smoke may have
favored the expansion of a highly metastatic subpopula-
tion of MCF7 cells. Although MCF10A cells had exhibited
increased intraductal survival and colonization after treat-
ment with CSE, these cells did not produce subcutaneous
tumors even after 43 weeks of exposure to CSE.
CSE causes changes in stem cell markers in MCF 10A and
MCF7 cells
Self renewal is a critical component of tumorigenesis
[11]. Thus, we analyzed how CSE affects the distribution
of specific cell surface markers that are associated with
tumor initiation and self renewal, specifically ALDH1 ac-
tivity, high CD44/low CD24, CD49f and CD133 [19-21].
FACS analysis showed a sharp change in the distribution
of CD44 and CD24 in CSE-treated MCF 10A and MCF7
Figure 3 Cigarette smoke facilitates intraductal colonization of MCF 10A cells and distant metastasis of MCF7 cells. (A-B) H&E and FITC/
DAPI staining of mammary gland sections from NSG immunodeficient mice injected intraductally with 100,000 control or 0.5% CSE-treated MCF
10A or MCF7 cells. Each mouse was injected at two sites. MCF10 A cells were injected into 3 mice and MCF7 cells into 2 mice for a total of 6 and
4 sites respectively. Two magnifications are shown. The xenografts were analyzed via immunoflourescence using a FITC antibody specific for
human cytokeratin-18. (C) Growth of subcutaneous xenograft tumors from control and CSE-treated (0.5%) MCF7 cells. Each mouse (n=5) was
injected at one site. Mean ± SD of five replicates are shown. (D) H&E staining of sections of lung and liver containing metastatic colonies from
three representative NSG immunodeficient mice subcutaneously injected with 750,000 MCF7 cells treated with 0.5% CSE. Two additional mice
were analyzed by gross pathology for a total n=5.
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exposure to 0.5% CSE, at least two cell populations with
substantially increased CD44 and lower ALDH activity
emerged. In one of these populations the expression of
CD24 was particularly low (Figure 4, left panels). In
MCF10A cells, the distribution of CD49f was virtually
unaffected by treatment with CSE, and the cells appeared
uniformly CD49f+ (not shown). A small number of
CD133+ cells that were entirely distinguishable from the
CD44hi cells were present in MCF 10A cells treated with
0.5% CSE, while untreated cells were CD133- (not shown).
MCF7 cells are a mixed population of CD44+ and CD44-
cells, but are uniformly CD24+ (Figure 4, right panels).
CSE treatment caused a shift to the CD24+/CD44+ quad-
rant, (76.8% to 93.1%) and an increase of CD49f positivity
in a portion of the CD44+ cells (18.4% to 29.9%). These re-
sults indicate that chronic low-dose exposure to cigarette
smoke can alter cellular distributions of markers associ-
ated with self-renewal and stem-like properties.Exposure of mammary epithelial cells to CSE affects the
expression of genes associated with EMT and
tumorigenesis
Two clones, designated SC1 and SC2 were isolated from
MCF 10A cells exposed to 0.5% CSE for 13 weeks and
expanded in the same concentration of CSE for 8 add-
itional weeks, at which time total RNA was isolated for
microarray and qPCR analysis. In addition, protein lysates
and genomic DNA were prepared from independent
samples treated with CSE for 21 weeks. The microarray
analysis identified 186 unique genes that were upregulated
and 308 unique genes that were downregulated at least
two fold in both MCF 10A CSE clones (Additional file 1:
Table S1). The expression of selected genes was verified
by qRT-PCR or Western blot analysis (Figure 5), focusing
on those genes associated with the phenotypes that we
had observed, namely EMT, invasion and metastasis. E-
cadherin and vimentin, which are associated with an epi-
thelial state [22,23], were downregulated and upregulated
Figure 4 CSE causes changes in stem cell markers in mammary epithelial cells and breast cancer cells. FACS analysis of MCF 10A cells
treated with CSE for 30 weeks and MCF7 cells treated with CSE for 17 weeks. Cells labeled with isotype control antibodies, or incubated with
DEAB (negative control) are shown in grey. Cells labeled with specific antibodies, or by aldefluor reaction are in shown in black and the
percentage of cells in each quadrant is shown. MCF 10A: quadrants were established to include 99.9% of CD24+/CD44+, or ALDEFLUOR+/CD44+
mock treated cells; cells with increased CD44 positivity (circled) are concentrating in the lower right quadrants after CSE treatment, indicating loss
of CD24 positivity and ALDEFLUOR signal. MCF7: quadrants were established to include 99% of signal from isotype antibody (negative); mock
treated MCF7 cells consist of a mixed population of CD44+ and CD44- cells, uniformly CD24+; CSE treatment caused a shift to the CD24+/CD44+
quadrant, and an increase in CD49f+ cells.
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analysis (left panel) and PCR (right panel) at 21 weeks
(Figure 5A). Similar changes were observed by Western
blot analysis for MCF7 cells; however, vimentin data is
only shown for a 0.25% CSE treatment (Figure 5A, left
panel). Decreases in occludin, and increases in N-cadherin
and fibronectin, which are also associated with a mesen-
chymal state [22], were observed in MCF10A cells treated
with CSE for 21 weeks (Figure 5B left panel). In addition,
we observed dysregulation of occludin and N-cadherin in
an independent RNA sample of MCF 10A cells treated
with CSE for 40 weeks (Figure 5B, right panel). We also
observed a general downregulation of keratins (Additional
file 1: Table S1), which is another hallmark of EMT [22].
Several members of the claudin family of tight-junction
proteins were downregulated (Figure 5C), which fits with
the observed increased motility induced by CSE treat-
ment. The EMT-promoting transcription factors TWIST1,
TWIST2, ZEB1, ZEB2, and FOXC2 were upregulated,
while FOXC1 and SNAI1 (Snail) were downregulated by
CSE in MCF 10A cells (Figure 5D). These transcription
factors can be induced through TGF-β signaling [24,25],
and we observed that TGF-β receptor I and III (TGFBR1,
TGFBR3), and TGF-β2 (TGFB2) were upregulated in
MCF 10A cells treated with CSE (Figure 5E). Some of
these gene expression changes were significant in only one
of the two CSE-treated MCF 10A clones indicating vari-
ability in the response to smoke exposure. Upregulation of
TWIST1 and TWIST2, as well as of TGFBR3 was also ob-
served in MCF 10A treated with CSE for 40 weeks,together with TGFB1, but not TGFB2 (Figure 5F). Since
exposure to cigarette smoke has been previously linked to
epigenetic silencing in human cancer [26,27], we investi-
gated if promoter methylation could be responsible for
gene downregulation in our model. We used a DNA
methylation array to estimate the proportion of methyl-
ated loci (beta-value) in MCF 10A cells treated with CSE
for 21 weeks (Additional file 2: Table S2), focusing on sites
located within promoter CpG islands. The beta value of
one occludin probe increased from 0.11 to 0.50 after
treatment with CSE, indicating a substantial increase in
methylation. Similarly, the beta-value of one claudin 1 site
increased from 0.06 to 0.55. None of the other down-
regulated genes that we had validated up to this point
were affected according to this analysis. However, we
observed increased methylation of estrogen receptor beta
(ERβ; 0.17 to 0.72), which can act as a tumor suppressor
in the mammary epithelium [28]. Western blot analysis
showed that the expression of ERβ was reduced in MCF
10A and MCF7 cells treated with CSE (Figure 6). Al-
though our data are in agreement with other published re-
ports and suggest that this receptor may be epigenetically
repressed by cigarette smoke, we cannot discount alterna-
tive transcriptional mechanisms and processes related to
protein degradation or decreased stability.
Discussion
After many years of debate, there is now ample proof
that tobacco smoke increases the risk of breast cancer.
Multiple studies, including some published after the last
Figure 5 Exposure of mammary epithelial cells to CSE leads to gene expression changes indicative of EMT. (A, left panel) Western Blot
showing upregulation of Vimentin and downregulation of E-cadherin in MCF10A and MCF7 cells exposed to CSE for 21 weeks. (A, right panel)
qRT PCR analysis showing downregulation of e-cadherin mRNA and upregulation of Vimentin mRNA in two MCF10A subclones after 21 weeks of
exposure to 0.5% CSE. (B) qRT PCR analysis showing downregulation of occludin and upregulation of N-cadherin and fibronectin in two MCF10A
subclones at 21 and 40 weeks of exposure. (C-F) qRT PCR analysis of EMT genes in MCF 10A mammary epithelial cells exposed to 0.5% CSE for
21 weeks (clones SC1 and SC2) or 0.5-1.0% CSE for 40 weeks (without subcloning). Data in bar graphs are mean ± standard deviation of 3
replicates; *P<0.01, **P<0.001.
Figure 6 Exposure of mammary epithelial cells or breast cancer
cells to CSE causes downregulation of ERβ. Western blot analysis
of ERβ in MCF 10A mammary epithelial cells, and MCF7 breast
cancer cells. Whole cell lysates were homogenized in high salt RIPA
buffer and proteins were separated via 3-18% NuPage Tris-Acetate
gels, transferred to PVDF and immunblotted with anti-ERβ.
Enhanced chemiluminescence was used for visualization.
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the subject [29] show that active and passive exposure to
tobacco smoke increases the risk of breast cancer in
both premenopausal and postmenopausal women [1-5].
With the epidemiological evidence now conclusive, the
task remains to investigate the molecular mechanism by
which exposure to tobacco smoke, either voluntary or
involuntary, leads to increased breast cancer risk [5].
The response of breast epithelial cells and breast cancer
cell to cigarette smoke has been previously examined
[15,16,30,31], but these studies focused on short-term
treatment (up to one week) while we have analyzed the ef-
fect of continuous long-term exposure. We demonstrated
that chronic exposure to tobacco smoke in the form of
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lial cells, promoting the acquisition of mesenchymal traits
such as increased anchorage-independent growth, motility,
invasion, and the expression of markers associated with
self-renewal and tumor initiation. Numerous groups have
demonstrated the emergence of a CD44+/CD24-/low
stem-like signature from CD44+/low/CD24+ cells upon
the induction of an EMT phenotype characterized by
loss of E-cadherin and gain of vimentin [11,32]. The
CD44+/CD24-/low phenotype has been consistently asso-
ciated with self-renewing mammary epithelial cells,
which are also more tumorigenic and basal-like than
CD44+/CD24+ cells [33]. Similarly, we showed that
treatment of MCF 10A cells with CSE leads to the emer-
gence of a CD44hi/CD24low population, and our in vivo
experiments demonstrated that CSE-treated MCF 10A
cells have increased survival and colonization ability.
Although MCF 10A cells did not become malignant,
treatment of the MCF7 cancer cell line led to increased
metastatic potential, consistent with published evidence
that the differentiation state of the cell of origin is a
strong determinant of the cellular phenotype of the final
transformed state [34]. Other studies in animal models
have previously shown that tobacco smoke can increase
the risk of metastasis from breast cancer, but this has
been attributed mainly to smoking-induced inhibition
of host antitumor immune defenses, or to damage of the
host tissue [35,36]. In contrast, our data from ex vivo ex-
posure followed by orthotopic or subcutaneous transplant-
ation into mice indicate that tobacco smoke can directly
affect the ability of breast epithelial cells to invade or
metastasize, independent of other cigarette smoke effects
on the host and stromal environment.
The phenotypical alterations induced by cigarette
smoke were accompanied by multiple gene expression
changes. We concentrated our analysis on genes associ-
ated with EMT, loss of tumor suppression and the acqui-
sition of malignancy traits. Our data indicates that ERβ
is epigenetically repressed by tobacco smoke, which is
consistent with a recent study showing that methylation
of ERβ is a frequent event in breast cancer [37]. Con-
trary to the better known and structurally similar ERα,
ERβ does not induce mitogenic response and can reduce
basal, hormone-independent cell proliferation [28]. ERβ
is widely expressed in normal mammary epithelium, but
frequently lost in breast cancer, where its presence gen-
erally correlates with better prognosis [28,38]. Knock
down of ERβ in MCF 10A or MCF7 cells was shown to
cause a significant growth increase of both cell types in
a ligand-independent manner [38], while expression of ex-
ogenous ERβ in the receptor negative breast cancer cell
line MDA-MB-231 inhibited proliferation [39]. Cigarette
smoke also caused downregulation of claudin 1, 3, 4, 7,
and 8. The claudins are integral components of tightjunctions, and their expression in cancer appears to be tis-
sue specific, with some claudins downregulated in certain
tumors and upregulated in others [40]. A small subgroup
of breast cancer has been identified as expressing low
levels of claudins, and is referred to as the “claudin low”
group [41-43]. Claudin low tumors represent 12-13% of
breast cancers, are generally basal like, and overexpress
EMT markers [41-43]. Mouse claudin-low tumors gener-
ated in a p53-null animal model were found to be mark-
edly enriched in tumor-initiating cells [44]. Consistently,
our claudin-low CSE-treated breast cells are more tumori-
genic than untreated cells, and exhibit gene expression
changes indicative of EMT, such as downregulation of E-
cadherin and occludin, and upregulation of N-cadherin, fi-
bronectin and vimentin. Downregulation of occludin can
reduce cancer sensitivity to apoptogenic factors by modu-
lating apoptosis-associated genes. In addition, occludin
decreases cellular invasiveness and motility, thus its
downregulation can potentially favor cancer metastasis
[45]. The downregulation of occludin and claudin 1 [46]
may also be the result of epigenetic regulation, since we
have observed increased methylation at the promoter of
these genes and in the case of claudin 1, the gene can be
re-expressed with demethylating agents such as 5-
azacytidine and decitabine [46]. CSE treatment upregulated
TGFBR3 and TGFB2 in MCF 10A cells, which is consistent
with the reported observation that endothelial cells under-
going EMT express TGFBR3, and TGFBR3-specific anti-
sera can inhibit mesenchyme formation and migration
[24]. Moreover, ectopic overexpression of TGFBR3 in non-
transforming ventricular endothelial cells conferred trans-
formation in response to TGFB2 [24]. Since we observed
upregulation of TGFBR3 and TGFB2 in MCF 10A cells
that are undergoing EMT-like changes, but are not com-
pletely transformed by cigarette smoke, our results suggest
that overexpression of these two genes by cigarette smoke
may be a component of EMT that is not associated with
transformation. Alternatively, this could be a very early
event in transformation and cancer development. We also
observed that the EMT-promoting transcription factors
TWIST1, TWIST2, ZEB1, ZEB2 and FOXC2 were up-
regulated, while FOXC1 and SNAI1 (Snail) were down-
regulated by CSE. Except for the decreased SNAI1, these
data are consistent with recent reports that the MDA-MB
-231 and MDA-MB-435 basal B cell lines express higher
levels of fibronectin, N-cadherin, SNAI1 and ZEB2, and
lower E-cadherin and FOXC1 than the luminal epithelial
cell line, MCF7 [25]. The same study showed that
overexpression of TWIST1, as well as the EMT-promoting
factor TGF-β1, consistently upregulates ZEB1 and ZEB2
and FOXC2 in human mammary epithelial cells. Interest-
ingly, TGF-β1 is up-regulated by TWIST1, but is not re-
quired for TWIST1-induced up-regulation of FOXC2,
which occurs in mammary epithelial cells overexpressing
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tor [25]. Taken together our observations in the MCF 10A
breast epithelial cell line exposed to CSE are consistent
with a model of EMT where TWIST drives the transition
and upregulates FOXC2, ZEB1 and ZEB2, with potential
involvement of TGFβ signaling.
Conclusions
Our results indicate that chronic, long-term exposure to
cigarette smoke leads to a more aggressive and trans-
formed phenotype in human mammary epithelial cells,
and that the differentiation state of the cell at the time
of exposure may be a critical determinant in the pheno-
type of the final transformed state. Non-malignant,
human mammary epithelial cells (MCF 10A) exposed to
cigarette smoke in the form of CSE survived intra-
ductally in a mouse mammary gland many months be-
yond their normal capacity, and breast cancer cells
which normally do not metastasize in mice (MCF7),
formed metastatic colonies in the lung. All CSE-treated
cell lines showed EMT-like behavior including increased
anchorage-independent growth, increased motility and
invasiveness, and we observed an increase in markers of
self-renewing cells, along with accompanying gene ex-
pression changes indicative of EMT and malignancy.
Methods
Cell culture model of exposure to cigarette smoke
Cigarette smoke extract (CSE) was prepared weekly by
burning 2 complete 1R3F cigarettes (Kentucky Tobacco
Research and Development Center, Lexington, KY,
USA) and drawing the smoke by vacuum into 10 ml of
sterile PBS. CSE concentration was evaluated by meas-
uring the optical density at 502.4 nm, and diluted to O.
D. = 0.10±0.01 [47]. This solution was considered 100%
CSE. The concentration of nicotine was evaluated by
mass spectrometry as previously described [48]. The
100% CSE contained 253±22 μg/ml of nicotine which is
equivalent to 0.2 cigarettes/ml. Cigarette smoke con-
densate (CSC) was purchased from Murty pharmaceuti-
cals (Lexington, KY, USA) and is prepared by smoking a
1R3F cigarette on a smoking machine and collecting the
particulate matter from the side stream smoke onto a filter
for extraction with DMSO. Cell lines were purchased from
ATCC (Manassas, VA, USA) and cultured with either
CSE, or CSC refreshing the media and additives twice a
week (see Additional file 3 for media formulation).
In vitro transformation assays
Anchorage-independent growth was assessed by seeding
the cells on soft agar (0.4% top layer, 0.8% bottom layer);
and counting the colonies after 14 days using an inverted
microscope and 0.005% crystal violet for staining. Cell mi-
gration and invasion was assessed in Boyden chambersusing 8μm-pore inserts, with or without matrigel coating
(BD Bioscience, San Jose, CA, USA) according to the
manufacturer’s instructions.
Animal studies
NOD-SCID and NSG mice were purchased from The
Jackson Laboratory (Bar Harbor, ME, USA), and cared
for in strict accordance with an approved Johns Hopkins
ACUC protocol. Intraductal transplantation was performed
as described previously [18]. Briefly, 105 cells were injected
in the mammary ducts of immunodeficient female NSG
mice as 2 μL of single-cell suspension in PBS with 0.1%
trypan blue, using a Hamilton syringe with a blunt-ended
1/2-inch 30-gauge needle. At the indicated times, mice
were euthanized, and the mammary fat pads harvested and
fixed in 10% neutral buffer formalin. For xenografts, CSE
treated cells (106) were subcutaneously injected as a 50 μl
single-cell suspension in a 1:1 solution of media and BD
Matrigel Matrix (BD Bioscience). At the indicated times,
the mice were euthanized, and fixed by perfusion with PBS
followed by 10% neutral buffer formalin for necropsy. Fe-
male mice receiving MCF7 cells were implanted with bees-
wax pellets containing 20 μg of estrogen one day before
injection [49]. Paraffin embedded sections were analyzed
by standard H&E staining, and by immunohistochemistry
using a monoclonal antibody for human cytokeratin-18
(C1399, Sigma-Aldrich, St. Louis, MO, USA), and the
Mouse on Mouse (M.O.M.) Fluorescein Kit (Vector Labs,
Burlingame, CA, USA).
Flow cytometry
Fluorescence-activated cell sorting (FACS) was performed
on a BD Bioscience SLRII instrument. Cells were labeled
using the ALDEFLUOR® kit (Stem Cell Technologies,
Vancouver, BC, Canada), or the antibody conjugates listed
in the Additional file 3.
Analysis of gene expression and methylation
Microarray based gene expression and methylation ana-
lysis were performed at the microarray core of the
SKCCC using the Agilent Human 44K expression array
(Agilent Technologies, Santa Clara, CA, USA) and the
Infinium Methylation27 Array (Illumina, Inc., San Diego,
CA, USA) as previously described [50]. The data is depos-
ited in the GEO database under accession number
GSE42668. Quantitative Real-Time PCR analysis (qRT-
PCR) was performed using a 7500 Real-Time PCR System,
the High Capacity cDNA Reverse Transcription Kit,
TaqMan Gene Expression Master Mix, and the TaqMan
Gene Expression Assays listed in the Additional file 3
(Applied Biosystems, Foster City, CA, US). Western blot
analysis was performed as previously described [50] using
the antibodies listed in the Additional file 3.
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Additional file 1: Table S1. Summary of the results of the gene
expression microarray analysis. Probes showing a difference in gene
expression of 2-folds or more in at least one clone are shown. The
complete data is available in the GEO database under accession number
GSE42668.
Additional file 2: Table S2. Summary of the results of the gene
methylation microarray analysis. Probes showing an increase in beta-
value of 0.2 or more in CSE-treated MCF10A cells are shown. The
complete data is available in the GEO database under accession number
GSE42668.
Additional file 3. Cell culture media, TaqMan Gene Expression
Assays, and antibodies (western blot and flow cytometry) used in
this study.
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